Last updated: May 29, 2026

Application No. 18/155,740

CD3 BINDING ANTIBODIES

Final Rejection

Filed

Jan 18, 2023

Priority

Jun 21, 2016 — provisional 62/352,698 +4 more

Examiner

BRISTOL, LYNN ANNE

Art Unit

1643

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Teneobio Inc.

OA Round

2 (Final)

This examiner grants 64% of cases after interview

— +39.7% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 1139 resolved cases, 2023–2026

Examiner Intelligence

BRISTOL, LYNN ANNE View full profile →

Grants 64% of resolved cases

Career Allowance Rate

725 granted / 1139 resolved

+3.7% vs TC avg

Strong +40% interview lift

Without

With

+39.7%

Interview Lift

resolved cases with interview

Typical timeline

3y 4m

Avg Prosecution

59 currently pending

Career history

1205

Total Applications

across all art units

Statute-Specific Performance

§101

1.1%

-38.9% vs TC avg

§103

15.5%

-24.5% vs TC avg

§102

6.7%

-33.3% vs TC avg

§112

45.4%

+5.4% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1139 resolved cases

Prosecution Timeline

Jan 18, 2023

Application Filed

May 16, 2025

Non-Final Rejection mailed

Oct 15, 2025

Response Filed

Dec 03, 2025

Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/982,481

Patent 12630651

ANTI-SCLEROSTIN CONSTRUCTS AND USES THEREOF

3y 6m to grant Granted May 19, 2026

16/985,607

Patent 12622937

COMBINATION OF ONCOLYTIC VIRUS WITH IMMUNE CHECKPOINT MODULATORS

5y 9m to grant Granted May 12, 2026

17/782,417

Patent 12624100

HUMANIZED CLDN18.2 ANTIBODIES

3y 11m to grant Granted May 12, 2026

16/482,603

Patent 12617853

LOW PH PHARMACEUTICAL COMPOSITION COMPRISING T CELL ENGAGING ANTIBODY CONSTRUCTS

6y 9m to grant Granted May 05, 2026

17/768,701

Patent 12617843

HUMAN BROADLY NEUTRALIZING ANTIBODIES AGAINST THE MEMBRANE-PROXIMAL EXTERNAL REGION OF HIV ENV FOR VACCINE DESIGN AND INTERVENTION

4y 0m to grant Granted May 05, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4

Expected OA Rounds

64%

Grant Probability

99%

With Interview (+39.7%)

3y 4m (~0m remaining)

Median Time to Grant

Moderate

PTA Risk

Based on 1139 resolved cases by this examiner. Grant probability derived from career allowance rate.